Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
1.880
+0.060 (3.30%)
At close: Dec 20, 2024, 4:00 PM
1.970
+0.090 (4.79%)
After-hours: Dec 20, 2024, 5:56 PM EST
Sutro Biopharma Revenue
Sutro Biopharma had revenue of $8.52M in the quarter ending September 30, 2024, a decrease of -49.66%. This brings the company's revenue in the last twelve months to $160.96M, up 230.90% year-over-year. In the year 2023, Sutro Biopharma had annual revenue of $153.73M with 126.84% growth.
Revenue (ttm)
$160.96M
Revenue Growth
+230.90%
P/S Ratio
0.83
Revenue / Employee
$532,964
Employees
302
Market Cap
155.02M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Adaptimmune Therapeutics | 175.04M |
Seres Therapeutics | 126.33M |
The Joint | 120.80M |
Metagenomi | 55.08M |
Nanobiotix | 45.22M |
Cellectis | 36.04M |
STRO News
- 5 weeks ago - Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 weeks ago - Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference - GlobeNewsWire
- 7 weeks ago - Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML - GlobeNewsWire
- 2 months ago - Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum - GlobeNewsWire
- 3 months ago - Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology - Seeking Alpha
- 3 months ago - Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - GlobeNewsWire
- 3 months ago - Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 - GlobeNewsWire